Fluoxetine (FLX), an FDA-approved drug for clinical depression, has been recently identified to possess anti-NLRP3 activity, in contrast to several other antidepressants that do not block NLRP3 [24]. This evidence concerns the gene NLRP3 and depressive disorder.